Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Progression of prostate cancer following castration is associated with increased androgen receptor (AR) expression and signaling despite AR blockade. Recent studies suggest that these activities are due to the generation of constitutively active AR splice variants, but the mechanisms by which these splice variants could mediate such effects are not fully understood. Here we have identified what we believe to be a novel human AR splice variant in which exons 5, 6, and 7 are deleted (ARv567es) and demonstrated that this variant can contribute to cancer progression in human prostate cancer xenograft models in mice following castration. We determined that, in human prostate cancer cell lines, ARv567es functioned as a constitutively active receptor, increased expression of full-length AR (ARfl), and enhanced the transcriptional activity of AR. In human xenografts, human prostate cancer cells transfected with ARv567es cDNA formed tumors that were resistant to castration. Furthermore, the ratio of ARv567es to ARfl expression within the xenografts positively correlated with resistance to castration. Importantly, we also detected ARv567es frequently in human prostate cancer metastases. In summary, these data indicate that constitutively active AR splice variants can contribute to the development of castration-resistant prostate cancers and may serve as biomarkers for patients who are likely to suffer from early recurrence and are candidates for therapies directly targeting the AR rather than ligand.

[1]  S. Dhanasekaran,et al.  Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. , 2009, Cancer research.

[2]  Zhiyong Guo,et al.  A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. , 2009, Cancer research.

[3]  L. True,et al.  Tumor Suppressor BRCA1 Is Expressed in Prostate Cancer and Controls Insulin-like Growth Factor I Receptor (IGF-IR) Gene Transcription in an Androgen Receptor–Dependent Manner , 2009, Clinical Cancer Research.

[4]  L. Borsu,et al.  Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. , 2009, Cancer research.

[5]  L. Moretta,et al.  Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. , 2008, Cancer letters.

[6]  L. Butler,et al.  The contribution of different androgen receptor domains to receptor dimerization and signaling. , 2008, Molecular endocrinology.

[7]  D. Robins,et al.  Profiling Human Androgen Receptor Mutations Reveals Treatment Effects in a Mouse Model of Prostate Cancer , 2008, Molecular Cancer Research.

[8]  Gerhardt Attard,et al.  CYP17 inhibition as a hormonal strategy for prostate cancer , 2008, Nature Clinical Practice Urology.

[9]  D. Tindall,et al.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.

[10]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[11]  J. Beck,et al.  Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro , 2007, Molecular Cancer Therapeutics.

[12]  J. Scheiber,et al.  Alternative splicing of TGF-betas and their high-affinity receptors TβRI, TβRII and TβRIII (betaglycan) reveal new variants in human prostatic cells , 2007, BMC Genomics.

[13]  P. Nelson,et al.  Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. , 2007, Cancer research.

[14]  Frank Claessens,et al.  The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. , 2007, Cancer research.

[15]  P. Nelson,et al.  Combined In vivo Effect of A12, a Type 1 Insulin-Like Growth Factor Receptor Antibody, and Docetaxel against Prostate Cancer Tumors , 2006, Clinical Cancer Research.

[16]  P. Nelson,et al.  Persistent intraprostatic androgen concentrations after medical castration in healthy men. , 2006, The Journal of clinical endocrinology and metabolism.

[17]  P. Nelson,et al.  Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites. , 2006, American journal of physiology. Endocrinology and metabolism.

[18]  C. Haiman,et al.  Cyclin D1: polymorphism, aberrant splicing and cancer risk , 2006, Oncogene.

[19]  L. Klampfer,et al.  Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. , 2006, Current cancer drug targets.

[20]  H. Scher,et al.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  K. Tomer,et al.  Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer , 2005, Clinical Cancer Research.

[22]  C. Roberts,et al.  Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. , 2005, Cancer research.

[23]  S. Plymate,et al.  Androgen receptor (AR) expression in AR‐negative prostate cancer cells results in differential effects of DHT and IGF‐I on proliferation and AR activity between localized and metastatic tumors , 2004, The Prostate.

[24]  A. Freeman,et al.  Differential Expression of CD44 During Human Prostate Epithelial Cell Differentiation , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[25]  Desok Kim,et al.  The Androgen Axis in Recurrent Prostate Cancer , 2004, Clinical Cancer Research.

[26]  K. Haugk,et al.  Activation of pro-apoptotic p38-MAPK pathway in the prostate cancer cell line M12 expressing a truncated IGF-IR. , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[27]  M. Kattan,et al.  Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. , 2003, Cancer research.

[28]  R. Vessella,et al.  A novel method of generating prostate cancer metastases from orthotopic implants , 2003, The Prostate.

[29]  R. Vessella,et al.  LuCaP 35: A new model of prostate cancer progression to androgen independence , 2003, The Prostate.

[30]  R. Krick,et al.  Expression, alternative splicing and haplotype analysis of transcribed testis specific protein (TSPY) genes. , 2003, Gene.

[31]  R. Vessella,et al.  Establishment and characterization of osseous prostate cancer models: Intra‐tibial injection of human prostate cancer cells , 2002, The Prostate.

[32]  M. Gleave,et al.  Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. , 2000, Cancer research.

[33]  J. Eastham,et al.  Androgen receptor mutations in prostate cancer. , 2000, Cancer research.

[34]  M. Sadar.  Androgen-independent Induction of Prostate-specific Antigen Gene Expression via Cross-talk between the Androgen Receptor and Protein Kinase A Signal Transduction Pathways* , 1999, The Journal of Biological Chemistry.

[35]  E. Wagner,et al.  Control of cell cycle progression by c-Jun is p53 dependent. , 1999, Genes & development.

[36]  S. Maygarden,et al.  Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line , 1998, The Prostate.

[37]  V. Mahesh,et al.  Autoregulation of androgen receptor in rat ventral prostate: involvement of c-fos as a negative regulator , 1996, Molecular and Cellular Endocrinology.

[38]  J. Thrasher,et al.  The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen. , 1996, The Journal of clinical endocrinology and metabolism.

[39]  C. Jackson-Cook,et al.  Cytogenetic characterization of the human prostate cancer cell line P69SV40T and its novel tumorigenic sublines M2182 and M15. , 1996, Cancer genetics and cytogenetics.

[40]  H. Klocker,et al.  Androgen receptor status of lymph node metastases from prostate cancer , 1996, The Prostate.

[41]  G. Buchanan,et al.  Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  H. Klocker,et al.  Mutant androgen receptors in prostatic tumors distinguish between amino‐acid‐sequence requirements for transactivation and ligand binding , 1995, International journal of cancer.

[43]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[44]  S. Plymate,et al.  Insulin-like growth factor-binding protein-3 expression and secretion by cultures of human prostate epithelial cells and stromal fibroblasts. , 1994, The Journal of endocrinology.

[45]  M. Karin,et al.  The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. , 1991, Biochimica et biophysica acta.

[46]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[47]  R. Vessella,et al.  Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.

[48]  L. Languino,et al.  Integrin signaling in cancer. , 2004, Cancer treatment and research.

[49]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[50]  R. Vessella,et al.  Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: The effect of bisphosphonate therapy on bone scintigraphy results , 2004, Clinical & Experimental Metastasis.

[51]  G Bartsch,et al.  Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. , 1999, Cancer research.